Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03247114
Other study ID # 1930
Secondary ID
Status Completed
Phase N/A
First received August 7, 2017
Last updated August 10, 2017
Start date February 22, 2015
Est. completion date May 22, 2015

Study information

Verified date August 2017
Source Unilever R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will consist of five occasions with one week in between. BOLD signal intensity of the hypothalamus will be measured using fMRI. Measurements will be done before and after drinking 300 ml plain water (reference) or water to which different sweeteners will be added.


Description:

The hypothalamus is known to be important for control of feeding behaviour as well as the regulation of temperature. Functional magnetic resonance imaging (fMRI) is a non-invasive method, which detects transient haemodynamic changes in the brain, using blood oxygen level dependent (BOLD) signal differences.

In order to investigate the role of hypothalamic neural activity in response to different sweeteners, fMRI will be performed before, during and after ingestion of 300 ml plain water or 300 ml water containing 50 g glucose, 50 g fructose, 50 g sucrose or 0.33 g sucralose (high intensity sweetener not providing energy). All beverages will be consumed at 22 °C.

The study uses a randomized cross-over design in 16 healthy male subjects with a normal body weight. There will be an interval of at least one week between the five occasions.

Blood Oxygen Level Dependent signal intensity of the hypothalamus will be continuously measured for 21 minutes (5 minutes baseline, 4 minutes during drinking and 12 minutes after drinking).


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date May 22, 2015
Est. primary completion date May 22, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria:

- Signed informed consent

- Age between 18 and 25 years

- BMI between 20 and 24 kg/m2

- Length between 170 and 190 centimetres

Exclusion Criteria:

- Diabetes or history of other disturbances of glucose metabolism (eg impaired glucose tolerance, hypoglycaemia).

- Any genetic or psychiatric disease (e.g. fragile X syndrome, major depression) affecting brain

- Any significant chronic disease

- Renal or hepatic disease

- Recent weight changes or attempts to lose weight (> 3 kg weight gain or loss, within the last 3 months)

- Smoking (current or last 6 months)

- Alcohol consumption of more than 21 units per week or use of recreational drugs at present or in the last year

- Recent blood donation (within the last 2 months)

- Recent participation in other biomedical research projects (within the last 3 months), participation in 3 or more biomedical research projects in one year

- Contra-indication to MRI scanning:

- Claustrophobia

- Pacemakers and defibrillators

- Nerve stimulators

- Intracranial clips

- Intraorbital or intraocular metallic fragments

- Cochlear implants

- Ferromagnetic implants

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Water
Water, 300 ml at room temperature
Glucose
Glucose, 50 grams in 300 ml water at room temperature
Fructose
Fructose, 50 grams in 300 ml water at room temperature
Sucrose
Sucrose, 50 grams in 300 ml water at room temperature
Sucralose
Sucralose, 0.33 grams in 300 ml water at room temperature

Locations

Country Name City State
Netherlands Leids Universitair Medisch Centrum Leiden Zuid-Holland

Sponsors (2)

Lead Sponsor Collaborator
Unilever R&D Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hypothalamic function in response to glucose, fructose, sucrose, and sucralose fMRI will be performed before and after ingestion Change from baseline (measured during 5 minutes before start of dinking) to post consumption (measured during 12 minutes after drinking). Drinking took 4 minutes.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1